Veradermics (US) is working on a new extended-release oral Minoxidil tablet to treat androgenetic alopecia (AGA). The product is called VDPHL01 and is currently in Phase 3 clinical trials. Also see my past posts on immediate-release low-dose oral Minoxidil and sublingual Minoxidil.
Note that this post was originally written in August 2024. The top half contains new updates in reverse chronological order.
Update: July 15, 2026
Veradermics VDPHL01 Delivers Positive Phase 2 Clinical Trial Results in Female Pattern Hair Loss
Even though I mentioned it in an old update, I forgot that Veradermics oral extended-release Minoxidil tablets were also being tested in females. Today, the company announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207’) evaluating VDPHL01 in females with mild-to-moderate pattern hair loss. More here.
- Participants achieved an average increase in non-vellus hair counts of 22.7 hairs/cm² and 23.3 hairs/ cm² in once daily and twice daily VDPHL01 4.5mg treatment arms, respectively. So almost a negligible difference, meaning that once daily treatment will likely be sufficient if these results hold in future trials. (Note that results in males that I discussed in April 2026 showed an increase of 30.3 hairs/cm² and 33.0 hairs/ cm² in once daily and twice daily VDPHL01 8.5mg treatment arms, respectively).
- 88.9% of participants in the once daily dose arm and 90.0% of participants in the twice daily dose arm achieved ‘improved’ or ‘much improved’ hair coverage. These classifications are based on the Androgenetic Alopecia Impact Rating Scale (AAIRS).
- There were no treatment-related serious adverse events (SAEs) or adverse events of special interest (AESIs) of cardiac origin. They do not mention anything about the most common side effect of oral minoxidil in the form of hirsutism (excess body hair, especially on the face).
- The ongoing Study ‘306‘ Phase 2/3 trial evaluating VDPHLO1 in females with pattern hair loss has an anticipated 1H 2027 readout date. Female trial enrollment link.
- They also mention that the topline results from the ongoing Study ‘304‘ second Phase 3 male trial are anticipated in the second half of 2026. Study ‘302‘ topline results for men were released in April 2026 (see my update further below).
Over 100,000 People Applied to Participate in Veradermics Trials
Also of interest, in a recent interview, Veradermics CEO Reid Waldman mentioned that over 100,000 people submitted and passed an online screener to try and participate in one of their ongoing trials. Quite extraordinary, although they were aided by a lot of digital advertising.
Update: April 26, 2026
Veradermics Announces Positive Phase 2/3 Clinical Trial Results for Oral VDPHL01
Veradermics just announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial to evaluate VDPHL01 for male pattern hair loss. The company’s stock price “MANE” rose almost 50% in early trading (it is currently up 35%). Make sure to go through their detailed Presentation Slides from today for more details, including very encouraging before and after photos. A quote from there:
VDPHL01 is designed to deliver nearly twice the total amount of minoxidil over 12h and maintains concentrations above the hair growth threshold twice as long vs. a 2.5 mg IR tablet.”
The trial (referred to as Study “302“) enrolled 519 patients who were randomized to receive either VDPHL01 8.5mg once daily (QD); VDPHL01 8.5mg twice daily (BID); or placebo. The results met all primary and all key secondary endpoints with statistical significance. There was a rapid and consistent response across patients, with a “robust” increase in hair count. There were no treatment-related serious adverse events (SAEs), nor any adverse events of special interest (AESIs) of cardiac origin. Key quote:
“Patients achieved an average increase in non-vellus hair count of 30.3 hairs/cm² (p<0.0001) and 33.0 hairs/cm² (p<0.0001) in once daily and twice daily VDPHL01 treatment arms, respectively. Those receiving placebo only showed a 7.3 hairs/cm² increase from baseline at Month 6.”
If such results were to hold for many years, this is truly impressive in my opinion. Even better than Finasteride (which inhibits the DHT hormone). But many people report that regular oral Minoxidil effectiveness declines over the years. So it is too early to get overly excited about extended-release oral Minoxidil just yet.
In terms of the less meaningful patient self-reported outcomes, following 6 months of treatment with VDPHL01:
- 79.3% of patients in the once daily dose arm and 86.0% of patients in the twice daily dose arm reported improvement in hair coverage on the Androgenetic Alopecia Impact Rating Scale (AAIRS).
- A surprisingly high 35.6% of placebo patients also reported an improvement in hair coverage on the AAIRS scale. I am not sure why we see so many studies give significant emphasis to self-reported outcomes.
- Additionally, 48.4% of patients in the once daily dose arm and 62.9% of patients in the twice daily dose arm reported “improved” or “much improved” hair coverage on the AAIRS (compared to 13.4% of placebo patients).
Veradermics believes that these results will lead to VDPHL01 becoming the first FDA-approved oral pill in nearly 30 years to treat pattern hair loss. Finasteride was approved in 1997. Note that Cosmo Pharmaceuticals’ Breezula is a topical solution that is also likely to get FDA approval (in 2027) to treat pattern hair loss.
Veradermics also announced that it completed enrollment in a second Phase 3 male trial (Study ’304’) in February 2026. Topline results are expected in the second half of 2026. They also have an ongoing Study ‘306’ Phase 2/3 trial evaluating VDPHLO1 in females with pattern hair loss.
VDPHL01 vs Rogaine Foam vs Oral Finasteride vs Oral Minoxidil
From the earlier linked presentation, they have an interesting hair growth comparison chart of: VDPHL01 versus Rogaine 5% Foam versus Oral Finasteride 1mg versus Oral Minoxidil 5mg. I will repeat that these results while impressive, are still not proven to be long-lasting.
Update: March 28, 2026
Faster Onset and Superior Efficacy of an Extended-Release Oral Minoxidil Tablet (VDPHL01)
Veradermics is presenting at this week’s American Academy of Dermatology’s 2026 AAD Annual Meeting in Denver. Prior to the presentation, CEO Reid Waldman spoke with “Managed Healthcare Executive”. He said that VDPHL01 produced faster, more consistent and greater hair growth than existing minoxidil treatments.
Update: February 4, 2026
Veradermics just completed a successful IPO that raised $256 million. It is now listed on the New York Stock Exchange under the ticker “MANE.”
Update: October 16, 2025
Veradermics Raises $150 million in Series C Financing
Yesterday, we heard that Pelage Pharmaceuticals (US) raised a massive $120 million in Series B Financing. In 2026, they plan to begin Phase 3 trials for their hair growth product PP405.
Today, we have news that Veradermics has raised an even larger $150 million in an oversubscribed Series C Financing. And this is after they raised $75 million in 2024 from Series B Financing. Such numbers are unheard of in the hair loss world. Veradermics is already conducting multiple Phase 3 trials for their hair growth product VDPHL.
For context, in 2021, the esteemed RIKEN and Dr. Takashi Tsuji of Japan were finding it difficult to raise $5 million and even asked me to help them with the goal. And in 2025, Yunce Biotech (China) is finding it tough to raise just $2 million to move forward with their hair cloning work. See the most recent comments from reader “Jan Miedza” in that Yunce post. And in late 2024, the much hyped Stemson Therapeutics (US) folded because it could not raise sufficient funds. Many other hair loss companies that I have discussed on this site in the past folded due to lack of funds to proceed with tedious clinical trials and approval processes.
In the earlier mentioned press release from Veradermics, they do not mention any other ingredient besides extended-release oral Minoxidil in this VDPHL01 tablet. The do provide some great before and after hair growth photos from their Phase 2 trials:
Update: September 29, 2025
Early Study Finds Extended-Release Minoxidil Grows More Hair
An optimistic summary of the results from the 20-person Phase 2 trial of VDPHL01, with the volunteers taking 8.5 mg VDPHL01 twice daily for 4 months. In the control groups, 33 patients received 5 mg immediate-release oral minoxidil once daily for 6 months; and 34 patients received 1 mL of 5% topical minoxidil solution twice daily for 6 months. Investigator Global Assessment (IGA) was the primary outcome that was measured, and the IGA ratings were made by blinded investigators.
The summary contains an interesting quote from Dr. Jerry Shapiro (who it is mentioned has a financial relationship with Veradermics):
“A longer time to sulfate is what we want, so if we keep the drug in the blood longer, there is greater sulfation and more activity.
Make sure to read my past post on Minoxidil sulfotransferase boosters and why Minoxidil requires sulfation in order to grow your hair.
Also of note, VDPHL:
“Offers an opportunity to maintain drug levels above those needed for therapeutic effect, but below those associated with cardiac adverse events.”
Update: September 21, 2025
Veradermics Extended Release Minoxidil for Hair Loss: Superior to Topical and Oral Minoxidil
Veradermics presented its smaller 20-person Phase 2 trial results at this month’s EADV Congress in Paris. A post about this on Instagram is causing some excitement. It has two slides in there, and I will paste the main points below:
- The doctor Congress attendee who made the Instagram post states that “Extended release oral minoxidil has superior increase in hair density compared to topical minoxidil and oral minoxidil. Phase 3 trials are underway.” So this confirms that VDPHL is extended release oral Minoxidil, even though Veradermics’ pipeline page still does not declare the key ingredient.
- 82% of VDPHL01 patients achieved moderate to great improvement versus just 20% of topical Minoxidil or low-dose oral Minoxidil users.
- There is superior efficacy (3.5 times higher IGA scores) in a shorter time frame (4 months versus 6 months) compared to “competitors”).
Update: January 2, 2025
Veradermics Phase 2/3 Clinical Trial Enrollment Link
Veradermics Phase 2/3 US clinical trial enrollment link is live. Their 40 plus locations are pretty widely spread across the country. Please note that we are not certain of the active ingredient(s) in this tablet. From the company’s patent, I previously guessed that it is an extended release oral Minoxidil, plus hopefully some other surprises (see bottom of this post). But it could end up being something totally different too.
The study involves 13 visits to a clinic over the course of 12 months. Participants will either get the new treatment or be part of the placebo group (that will still also get a tablet).
Update: December 11, 2024
Veradermics Raises $75 Million for Phase 2/3 Trials
Veradermics just raised $75 million in Series B financing (h/t “meko”). They have also initiated a Phase 2/3 trial for their lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA). The trial will enroll 480 patients across 44 sites in the US. Note that Veradermics also has an ongoing 20-patient Phase 2 trial for VDPHL. The company plans to report topline data from that Phase 2 study in the first half of 2025.
August 9, 2024
Veradermics VDPHL Tablet: Phase 2 Trials Begin
Veradermics is a US-based startup that is working on a new tablet to treat androgenetic alopecia (AGA). They just started Phase 2 clinical trials for VDPHL01 in male subjects with AGA. Only 20 patients are enrolled, and the completion date is listed as August 1, 2025. The trial will take place at Therapeutic Research’s center in San Diego, California. Note that VDPHL likely stands for Veradermics Pattern Hair Loss.
The tablet does not impact hormone levels as do dihydrotestosterone (DHT) inhibitors finasteride and dutasteride. Thus avoiding potential side effects. Veradermics’ CEO is a young dermatologist named Reid Waldman.
Modified Release or Extended Release Oral Minoxidil
The mechanism of action (MOA) and key ingredient(s) in this tablet are both confidential. However, when I searched through the company’s patent, it seems like the drug candidate will be a “modified release” oral minoxidil tablet. In the patent, they use the term “extended release (ER)”. Note that they do not use the term “sublingual minoxidil” anywhere in the patent.
Other Potential Ingredients in VDPHL
In the patent, they also have a massive list of 191 claims. Within that section, all of the following drugs are listed 11 times each:
- Setipiprant (11 times).
- Valproic acid (11 times).
- Cetirizine (11 times).
- Medrogestone (11 times).
For long time readers of this blog, setipiprant (and Kythera) will ring a bell. It caused so much excitement a decade ago. I cannot believe that the very optimistic 9-yr old audio interview with Kythera’s CEO is still online. Setipiprant is an oral antagonist to the prostaglandin D2 (PGD2) receptor.
I covered valproic acid and hair growth in detail in the past. Follica also has a patent that covers valproic acid and hair regrowth. Valproic acid activates the Wnt/β-catenin signaling pathway.
Cetirizine is a PGD2 inhibitor that has been shown to benefit hair growth even when used topically.
I have never covered medrogestone on this site before. Per Wikipedia, it is a progestin that is an agonist of the progesterone receptor and a weak anti-androgen. Progesterone is a female sex hormone that has beneficial properties towards hair growth.
VDPHL01 Clinical Trial Updated Links
Enrollment links:
- 70 patients (male and female).
- Start date = 2024-07-08.
- Completion date =2026-08-28.
- 480 patients (males only).
- Start date = 2024-11-06.
- Completion date =2026-07.
- 552 patients (females only).
- Start date = 2025-07-25.
- Completion date =2027-03.
https://ir.veradermics.com/news-releases/news-release-details/veradermics-oral-vdphl01-delivers-positive-study-207-phase-2
Thanks Rome.
https://www.biospace.com/business/hair-loss-biotech-veradermics-up-656-since-its-ipo-credits-the-obesity-boom
I read this article a few days ago and immediately thought of Pelage and the database of interested trial candidates they must be accumulating. I believe they had said something similar in terms of the ease of attracting trial candidates. It leads me to believe they may be further along than it appears in getting their Phase 3 launched. In contrast, Rodney Sinclair said just about the opposite.
Pinotq, Veradermics advertised a lot on Instagram (and even had a banner ad on this site for 6 months) while they were recruiting for trials.
Both companies raised major funds, though I am not sure if Pelage ever did much advertising on social media platforms. I am sure they will still get thousands of people interested in participating in their Phase 3 trials.
Pretty cool, I’ve been in the hair loss game for over 40 years. Used to hide my treatments as much as possible, it seemed embarrassing to be on them. These days treating hair loss is much more in the open which is a great thing. Excited to see the next FDA approved treatments finally hit the market after all these years. I hope VDPHL01 brings improvement to us that are already on oral/topical min, not just those starting out.
admin, what type of hairstyle will you go for once you get it all back?
Funny LJ. Doubt I can get it all back anytime soon…but in the long term, maybe this:
https://simple.wikipedia.org/wiki/Ronald_Reagan#/media/File:Ronald_Reagan_1985_presidential_portrait_(cropped).jpg
Classic choice, I’d go for an undercut James Darmody style
https://d2thvodm3xyo6j.cloudfront.net/media/2013/08/Michael-Pitt-600×338.jpg
Interesting point about the extended-release design nearly doubling minoxidil delivery over 12 hours compared to standard 2.5mg tablets. That feels like a meaningful step forward for sides, since the old immediate-release spikes can be rough on the heart for some people. Personally, I’d be curious to see how the twice-daily arm compares long-term, since maintaining that steady threshold seems key for consistent regrowth.
Big hair loss story in WSJ. Most of the story focuses on Veradermics’ drug. Just a passing mention of Pelage at the end of the story. That was free PR for Veradermics.
I doubt it was free.
Good results but for long term results finasteride- dut will be needed. This is just minox on steroids.
Hey admin and Yoda. hope you guys are doing well:) Nice to see some potential new treatments down the line. Breezula snd this oral minoxidil. Pretty much same technology like propecia and rogaine but reversing it lol. Well hopefully it works better than current treatments, but the pics weren’t too impressive tbh. Fingers crossed it works better for those on finasteride for added benefits.
Good to hear from you Mjones.
Mjones, a blast from the past! Let’s hope we’re celebrating new treatments finally available in a year that improve our results.
https://ir.veradermics.com/static-files/11e390e1-936f-4c55-abad-ed8e2df25870
Pretty impressive pictures here.
Thanks LJ. Make sure to refresh your browser too. I added a chart and a quote from there in the post 10 mins ago.
It’s interesting how we have different perspectives on what a picture of “good results” looks like. To me, those pictures are quite disappointing. I suppose I’m waiting for a picture of a hair loss cure here on Hair Loss Cure 2020. Things are slowly improving, but we’re not close yet.
Good news overall, like you mentioned Admin will be interesting how the results hold up for the long haul. I’m one who’s results from oral/topical min wanes over time, although fortunately not all the way back to baseline. Would’ve been interesting if they had subjects on minoxidil (topical and oral) or recently on and if they saw improvement with VDPHL01. With their subject criteria these results are for guys who were never on min or gave it up quite a while ago. For no good reason I bet most or all have never tried oral min before. Admin, while you can’t predict the future, would you feel that VDPHL01 and Breezula will both be commercially released next year?
Yoda, I would be very surprised if both are not released by 2028 at the latest. My bet is on 2027 for both.
Thanks admin, agree and optimistic we’ll see both released sometime next year. Hopefully they’ll even give an old guy like me a boost. Planning to use both and keep on my current regime except swapping standard oral minoxidil for Veradermics.
And then pp405 should be released shortly after if approved. Things are finally looking up for us AGA sufferers.
Let’s sure hope and that the PP405 results match expectations.
PP405 likely comes in 2029 (Phase 3 Study is a year long and has not begun, then there’s probably a safety confirmation trial and then NDA, which takes another 10 months.
New product from the Hairdao – they announced an oral Minox product a couple of weeks ago. Apparently it has a formulation with time-release similar to Veradermics.
https://anagen.xyz/products/minoxidil-5-mg
https://nitter.net/anagenxyz/status/2046606851203039648#m
Why does Veradermics need 250 million again? Kinda ridiculous.
Hairdao has become quite aggressive in their tone on social media which I don’t like. But they cook and deliver. Obviously they have some bright minds on the helm.
The topical Dut is also next-gen. Just waiting for better data from them.
Woah! Nice find!
Do you have a sense of what makes the “precision” topical dutasteride worth it? Right now I use Ulo’s low dose formulation.
Just watch their videos, they are quite active.
I think they tested 60 delivery vehicles and found one that is significantly more effective than the others.
Nice find!
Anecdotally, do these guys have a good rep/good testimonials?
I’ve been curious about topical Dut but being a guy, I’d be concerned about potential sexual sides even if topical reduces the risk.
Here’s their pipeline. They have a lot of candidates.
https://nitter.net/pic/orig/media%2FHGcTeUUWsAA9jDm.jpg
Interesting! I appreciate their moxy.
https://www.yahoo.com/lifestyle/article/they-want-better-health-care–so-theyre-turning-to-crypto-startups-210244117.html
https://www.404media.co/inside-the-discord-community-developing-its-own-hair-loss-drugs/
ChatGPT now puts the race between Clascoterone and VDPHL01 at “neck-and-neck” in terms of timelines:
Updated side-by-side (most realistic) (all from ChatGPT)
Drug Stage (2026) Mechanism Expected US Launch Confidence
Clascoterone Phase 3 done Topical anti-androgen Late 2027–2028 ⭐⭐⭐⭐
VDPHL01 Phase 2/3 + Phase 3 Oral minoxidil (extended-release) Late 2027–2028 ⭐⭐⭐⭐
Pyrilutamide Phase II/III Anti-androgen ~2027+ (uncertain US) ⭐⭐⭐
PP405 Phase 2 Stem cell activation ~2028–2029 ⭐⭐
And ABS-201 in 2030, Lord willing.
Veradermics not far off $3B market worth now and Cosmo hovering around $2B.
You can mimic VD by taking 1mg of minoxidil every 1 hr for let’s say 10 hrs a day, but you need to have a good dedication for that.
https://www.businesswire.com/news/home/20260318655567/en/Veradermics-Announces-Presentations-on-VDPHL01-and-Patient-Experiences-With-Pattern-Hair-Loss-at-2026-American-Academy-of-Dermatology-Annual-Meeting
https://youtu.be/X0qfwlLjMzE?si=U6sp1P042b97M3kY
Thanks for sharing! My question with this is which side effects will.it reduce. Like to hypotension is obvious, but what about things like edema, weight gain, etc? Especially, since the case is it this formulation will allow you to take higher doses not that it will be effacious at lower dosages.
I don’t know about all that, but look at this company’s stock performance since it floated – https://g.co/finance/MANE:NYSE?window=1M, nearly $2B from phase 2 results. Couple that with Cosmo (https://g.co/finance/COPN:SWX?window=6M), most of whose value seems to come from their announcement of CB-03-01 results, and you have more than $4B riding on upcoming treatments now…
https://ir.veradermics.com/news-releases/news-release-details/veradermics-completes-enrollment-second-pivotal-phase-3-clinical
Impressive. This is the first company I have seen with real legitimate investors and a solid IPO to follow.
https://finance.yahoo.com/news/hair-loss-biopharma-firm-veradermics-031910770.html
Seems a as though the IPO was successful.
They filed for an IPO last Friday (https://www.reuters.com/business/healthcare-pharmaceuticals/biopharmaceutical-firm-veradermics-files-us-ipo-2026-01-09/) and in their filing paperwork disclosed more detail about the recent phase 2 study (https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm) on page 100 and following.
Photos look decent – not sure if that had been shared before.
This is interesting as I believe it’s the first biotech/pharma focused on AGA to make it out of VC to an IPO, I wonder why they’re floating so soon after the series B?
Also, I’m sure they used to have more drugs in their pipeline, but it seems now only VDPHL01 is listed.
This looks as though it’ll be the first proper drug available to treat this disease; I’ll almost definitely be taking it to bridge the gap until hopefully pp405 and/or ABS201, although I’m not crazy about the idea of hirsutism as a side effect.
these pictures are fantastic! can’t wait for this one…I can use this as a bridge until more cureable like pp405 comes out.
I wonder with results in 4 months is the well-known minoxidil dread shed avoided with the extended release.
Veradermics has comleted its Phase II/ III enrollment.
https://www.veradermics.com/veradermics-completes-phase2-3-enrollment
I’m confused I thought Veradermics was regenerating donor hair follicles on the back of the head? Was I wrong?
mm yes. veradermics is extended release oral minoxidil.
It’s minoxidil lol
Nice to see this moving along. Probably the most likely to reach market and would be a big boon for those who don’t want to try oral minoxadil off label.
Two questions:
1) Is it fair to say that if topical minoxidil has no effect at all (in my case) that this product won’t work either? I’d be happy with even a little more density.
2) Topical minoxidil isn’t that expensive, what price range do you expect it to fall into? (per month)
1. No that’s not fair to say because oral minoxidil is metabolized by your liver. Topical is an inactive form that’s converted into an active form by an enzyme in your skin that you may not have. You could respond to oral even if you’re not a responder to topical. You can try a topical minoxidil with tretinoin in it and it may increase your response. But it’ll probably be more expensive and require a prescription. I use this myself.
2. No idea, haven’t seen any data on potential pricing. But it’s probably going to be prescribed for cosmetic reasons so insurance won’t cover it and it’ll have to be somewhat reasonable. Far more expensive than topical minoxidil though is probably safe to assume.
Nobody wants to fund a cure, its all drugs to keep you coming back for more. I have been saying that for years.
Hold on woofy97, what about the developments at kintor? What about pp405? Do you feel these scientists are not honestly working to find a cure? Maybe a “a cure” is also not a realistic goal, but do you feel these companies are not trying to better the options in this field?
At this point, it doesn’t matter if they don’t find a definitive cure, I just want them to find something that actually works, something that can regrow most of the hair I’ve lost. My hair is so thin that I now always have a hat on to cover the mess, and always wearing a hat really sucks.
Tim Pool, is that you?
…yet here you are…
Thats just fantastic news in the last days … btw they also update the pipeline
https://www.veradermics.com/pipeline
Now that I’ve heard about this 150 million for a drug that contains minoxidil, I’m much less optimistic about Pelage and its pp405… bad news.
My god.. what a negative mindset. Why can you not be optimistic about both? It’s objectively good news for both companies.
After 35 years of waiting it is hard to be optimistic. My best years are long gone.
I understand that Lorence, 35 years is a long time. I sometimes also look at an 6 year old kid with his balding dad thinking: you might be lucky when you grow up..
This kind of angers (actually a lot) that companies like Pelage and Veradermics have received +$100M investments but Stemson couldn’t…
Some people are never satisfied.
You were happy with the whole Stemson situation? Interesting.
I never followed it that closely, same with Yunce, seemed like pie in the sky to me. Certainly not dwelling on it days after announcements of $400M being invested in upcoming treatments.
If it were that great they’d get the money, not a big mystery there. Geez, you fan boys never cease to amaze me.
Boooooo!!!!
My thoughts exactly.
Fan boys or Boo LJ? :-) I could never figure out this whole “Anchorman” man approach to treatments. Anchorman as in the movie when the three news teams had a rumble. Who cares what horse wins the race, as long as one finally wins soon. As for treatments that die or can’t raise funding, there’s a reason, ultimately they don’t work for whatever reason, e.g. effectiveness, safety, cost, just like any other product.
Don’t know if I’d use the word fanboys, but I definitely do feel beggars can’t be choosers.
One day after Pelage, a new funding record is set?
https://www.fiercebiotech.com/pharma/veradermic-looking-tousle-hair-loss-market-locks-down-150m-series-c
That‘s insane. What’s going on?
Stemson would have needed what? 70 million?
And all that for oral minox…I only saw one patient photo and that was really underwhelming.
They must see better results too, otherwise you don’t fund this amount.
The results here look decent
https://www.veradermics.com/veradermics-announces-150million-seriesc-financing
I mean those pictures look fantastic. I’d be stoked to get those kind of results. Those are transplant level results. I have been on fin/dut and topical min (switched to sublingual Minoxidil since last week) for almost a year now and I am barely improved since baseline. I am still bald AF. If I could get results like this, it would be a miracle for me.
Decent?! Great, you mean.
Well, they don’t all look great do they?
They do to me.
Ok thanks, I didn’t see these ones before. I hope they are not curated.
If these are the standard results, then inject it into my veins :-)
Suddenly it doesn’t look so bleak anymore.
Hello,
When will new technology/medicine that is actually beneficial become commercially available? Even if it’s not like hair cloning, but something like Pelage that wakens the dormant follicles? So like not as exceptional as regrowing a full head of hair, but at least revives some of the follicles that remain dormant under fin+min. Thank you.
https://www.instagram.com/p/DO0bMQBDWsb/
Don’t these results look pretty good?
If what I’m reading is correct I’d be a buyer. Seems to help with dreaded MPB itch, scaling and pain as well. Thanks for posting LJ.
Yoda, to clarify I believe the improvements for scale and itch were monitored in the 2nd study of a jak inhibitor for patients with refractory LPP.
That being said the results for Veradermics based on the IGA improvement seems significant.
Does anyone know what IGA points mean in NW scale terms (if anything)?
Thanks for clarifying TP, my ADD with reading this stuff gets the best of me! Why I use phrases like “if I’m reading this correctly” not studying closely or hanging on every word, glad I at least got the improvement right….and still probably a buyer!
Thanking you here LJ! Have updated the post.
Any idea of a potential commercial release for this? Wild guess?
The trial ends in July 2026. Hope they release it in 2027.
Admin – I think someone posted in this thread earlier this summer that they tacked on additional Phase III time on ClinicalTrials.gov to project the final leg of the trial might end December 2026. But thanks for posting this. Great news on a bad day.
Crap, I was hoping within a year. Thanks though Admin.
Admin, what do you think will be better: sublingual (Sinclair) or Veradermics extended release?
Efficacy and side effects?
Technically you don’t have to wait for sublingual Minoxidil. I just got a sublingual min prescription from my derm to a compounding pharmacy. If you have a dermatologist that is open to it, compounding pharmacies can make sublingual Minoxidil troches/lozenges for you to put under your tongue now. No need to wait for Dr Sinclair, you can get this now.
Yes I know – it would be interesting though to know the differences between those two methods.
I dread side effects.
Ben, check out my new update on top of the post after refreshing the page. An interesting point about greater sulfation with extended release oral Minoxidil.
Hard to tell which one will be more effective at this stage betweel sublingual and extended release. But I would not be surprised if some people end up combining the two (like the 1 day dutasteride, 6 day finasteride type of strategy).
The only side effect from oral Minoxodil that I do not like is that it seems to have made some of my facial hair grow more rapidly, and maybe give me more fuzz on the forehead.
Darkprince, what country are you in and if in US what pharmacy? What mg did your Doc prescribe? Have you been on traditional oral min? Please keep us updated on your results with the compounded sublingual min!
I am in the US. My derm is using Noblesville compounding pharmacy in Noblesville, Indiana. Yes I was on traditional oral 5mg I believe a year ago. Had to stop after a few weeks due to chest pain. My dosage this time is 2.5mg sublingual. I will keep you updated for sure!
Much appreciated Dark, I hope it works well for you from a side effect standpoint and effectiveness. I’m on 10mg oral and compounded 8% topical 2x a day (other stuff in that too), not to mention Kirkland 5% foam in the very early in the am when drinking coffee, working out, etc before showering for the day. No sides but have lost some ground and looking for the next thing.
I’m surprised u lost ground on 10mg oral min Yoda.
Results:
https://www.reddit.com/r/tressless/s/1eMJl8JGVz
Looks pretty good!
Here is the link for female enrollment for Phase 3 (based on the timeline of the website not the study enrollment page). I wonder how it is hormonal if medrogestone is listed in the patent.
https://www.phlstudy.com/female/
This also works for the male recruiting: https://www.phlstudy.com/male/
Doubt it can be the VDPHL trial unless this guy did not tell them that he was also taking Finasteride:
“Oral Fin everyday and some type of minox (it’s a research study with a greater minox dosage than available in market or placebo…though I don’t think it’s the latter).”
https://www.reddit.com/r/tressless/comments/1ldcp6j/progress_pictures_18_ish_months/
The link in the Reddit-post doesn’t work anymore…maybe that guy thinks that the Veradermics tablet includes Fin?
I‘d like to see the effects of their treatment.
He (“Substantial_Lab_7131”) removed the original comment and great before and after results photos… but kept his comments underneath the post.
One reader asked him 13 hours ago if this was VDPHL01, and he answered “yep” an hour ago.
admin, did you see this, i think this could be a game changer.
https://www.reddit.com/r/tressless/s/oaojZP7Ykd
Thanks, had not seen it. The OP is in the trial and took those photos himself. Hopefully it is legit, though I am a bit suspicious since it is his first ever post on Reddit.
The results look better than just plain old oral Minoxidil.
By my estimates, Veradermics is about on schedule to be released right around the time Breezula is. Lots of assumptions there – like both get final approval. This is why I think Breezula is overly optimstic in their market share projections. And right on the heels of both of them could be Pelage if that gets approved (a year or two later). So, for some market entrants, it might be too late. But the more, the merrier. JMO
I like your optimism, it’s quaint. We should be so lucky if any/all get approved on schedule, would be ecstatic if even one does.
Mangoceuticals …. pharmaceutical-grade chewable
Is this the same approach as Veradermics or Samson Clinical?
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mangoceuticals-is-reengineering-the-self-care-blueprint-with-better-p-1018191
Another Phase 3 till 11/2026
https://clinicaltrials.gov/study/NCT06972264?cond=Androgenetic%20Alopecia%20%5C(AGA%5C)&rank=1
Pictures from the trial:
https://www.reddit.com/r/tressless/s/WeWnYKgwVt
That’s actually really disappointing. And this company got 75 mil funding? What the heck.
I mourn Stemson, what could they have done with the money.
Holy cow – I am very underwhelmed by those results. I hope that is not the typical ‘great’ responder. But then again, I only would use it as a bridge to Pelage (assuming either makes it to approval).
If it’s on Reddit it must be true.
So we could see this hitting the market by 2026/27? I for one, am very excited about this. oral Minoxidil on higher dose without side effects? Sign me up!
https://nypost.com/2025/02/07/health/new-hair-loss-treatment-being-tested-with-paid-volunteers/
Interesting, what’s the best estimate this would be commercially available if the clinical trials are successful?
I am moderately optimistic for this one.
I don’t know why they make such a secret of the ingredients – it is very likely Minox. Kinda ridiculous.
If they tweak the formula to more efficacy and less side-effects it’s definitely a win.
If it has the same results as regular oral Minox then I don’t know how they market this. That’s been available for many years for affordable prices.
It’s a bit mysterious.
I wonder if it will have more staying power than oral min…for me anyways. I had great gains with oral min about 5 years ago however they only held for about 3 years then lost ground. Not back to baseline, however not as thick and lustrous as it was at the pinnacle of my success. Pretty similar to my experience with topical min way back when and whenever I’d increase the concentration, an initial boost then backtrack. Hopefully they solve that part of the equation.
That would be a HUGE bummer. To psychologically think that you beat hair loss…and then have it come back again. Lame.
I’m in San Diego too Bro, Clairemont area. Keep us posted on your results. Oh, and just because that’s my outcome doesn’t mean other’s will suffer the same fate. Although our friend from down under Mr. SummyKim lost ground as well, I think under similar circumstances but could be wrong.
I believe that I’m part of this clinical trial, although I’m not sure if I’m phase 2 or phase 2/3. I am taking 8.5mg of VDPHL01 twice daily. I’ve been told that it’s a specially formulated version of minoxidil that is timed and/or extended release. I’m about to hit month 6, and my results have been slow but very promising.
From Veradermics’ LinkedIn:
Veradermics is at an exciting inflection point: after recently closing our Series B funding we are growing our Clinical Operations team to support our current Ph.2 and Ph.3 clinical trials. To help drive this next chapter, we’re searching for *2 Senior Clinical Trial Project Managers* to oversee trial execution and CRO partnerships.
Can we assume this Phase II / III trial will be the final trial? Seems odd if they could combine Phase II / III stages and make it the final trial unless there is no novel compound in it that hasn’t already been FDA approved.
A link to this story arrived in my email box this AM:
https://www.businesswire.com/news/home/20241211308760/en/Veradermics-Raises-75-Million-in-Series-B-Financing-and-Initiates-Phase-23-Trial-for-Hair-Loss
So considering early clinical and preclinical costs, they’ve invested $100 million to get approval for oral minoxidil(!). Crazy times, still, I suppose if it works….
See the bottom third of post.
Admin – what do you make of the money involved here? It seemed like it was a big deal when Pelage raised $16.75 million followed by $14 million, but Vermadermics has raised $75 million (or $100 million?). Should this be topping our lists of treatments to follow?
If it is just oral Minoxidil with a better delivery process, then I am not overly excited.
Exicure raised an immediate $25 million from Allergan in 2019, along with potential milestone payments of up to $265 million. It did not result in anything so far.
Admin, Exicure stopped their hair loss R&D over two years ago:
https://investors.exicuretx.com/news/news-details/2022/Exicure-Inc.-Announces-Termination-of-AbbVie-and-Ipsen-Collaboration-Agreements/default.aspx
This investment must have been the single biggest blunder in the history of hair loss research.
After that, they struggled to keep going and are barely alive with their other programs.
Thanks Ben.
On a related note the case of Kythera is really crazy. In February 2015, the company purchased global rights to Setipiprant (see my CEO audio interview link at the bottom of this very Verademics post).
Then Kythera itself got purchased by Allergan in June 2015.
Then AbbVie purchased Allergan in 2020.
Is this the same drug as someone earlier mentioned? the high dosage oral Minoxidil without side effects? i remember someone taking 2x 8,75mg without any sides. don’t remember if it was here or on Reddit. that would be amazing. 15/20 mg oral Minoxidil without side effects would be basically a (very hairy) cure.
I made a post on Reddit a couple of months back, but I deleted it. I’m currently taking this medication as part of the trials. 8.5mg 2x/day. It’s been 5 months and I’m not a hyper responder by any means, but I’m personally pleased with the results.
Great to hear. Are you experiencing any sides with it? Are the results better than finasteride?
Sides: I had headaches the first couple of weeks, but that went away.
Fin comparison: I had a prescription for oral fin a few years ago, but I didn’t take it consistently and stopped after a couple of months of seeing no results. So, I can’t make a fair comparison.
Interesting the screeners eliminated anyone with prior minox use so as not to skew the results how did u get in the study.
From the exclusion criteria it’s looks as though that was use only within the previous 4 weeks, but the more important question is how does anon know he isn’t taking placebo?
Thanks for publishing my comment and correcting my mistake admin
Phase 2/3 started
https://clinicaltrials.gov/study/NCT06724614?cond=Hair%20Loss%2FBaldness&rank=1
Thanks, I updated the post with trial links on top. Seems odd to start Phase 2/3 trials before Phase 2 trials have ended, but I think I have seen this in the past too.
Hopefully the tablet has all the 5 ingredients that I discussed in this post.
Mixed phases have always gotten me confused:
will this phase 2/3 be enough, or they will have to do another standalone phase 3 after that?
Extended release minoxidil could be reasonably simulated by dividing the daily dose and taking every 3 hours as that is the half life. A lot of work but it would be interesting to see if it’s effective.
So to sum things up, in the hair loss world, we still are battling this thing with the same old rebranded, repackaged dinosaur era minoxidil or finasteride. This sucks.
Interesting. Curious how it’ll be minox (to some extent) but without the sides. Not sure how they’ll pull that off and if people with heart issues will be able to take it (many with heart issues can’t take oral minox). Also, why only 20 people in the trial? For something like this, that doesn’t make sense to me but I’m no expert on the rules and guidelines of clinical trials.
So it’s oral Minoxidil? That’s unfortunate, I do not tolerate oral Minoxidil at all, even on 1mg doses.
As far as I remember some research for oral valproic acid causes hair loss and topically increases hair growth.